Marini G, Simoncini E, Zaniboni A, Gorni F, Marpicati P, Zambruni A
III Divisione di Medicina Generale, Fondazione Beretta, Spedali Civili, Brescia, Italy.
Oncology. 1987;44(6):336-40. doi: 10.1159/000226507.
We report an update of our results of a trial of high-dose folinic acid (HDFA) and 5-fluorouracil (5-FU) in advanced breast cancer. Thirty-eight patients with advanced and mainly refractory breast cancer were treated with the following regimen: HDFA (200 mg/m2/day) and 5-FU (340, 370, 400 mg/m2/day) given immediately afterwards, for 5 consecutive days every 4 weeks. Of 36 evaluable patients, 3 achieved complete remission (8%) and 13 partial remission (36%) for an overall response rate of 44%, while 11 patients (30%) had stable disease. Thirteen out of sixteen responders (85%) were pretreated with some 5-FU-containing regimens. The median duration of response was 9.6+ months, the median survival for responders and for patients with stable or progressive disease was 19.9+, 18.8+ and 9 months, respectively. The overall toxicity was acceptable: while hematological toxicity was very mild, oral mucositis, diarrhea and conjunctivitis were major side effects. These results seem very promising and deserve further evaluation.
我们报告了一项关于高剂量亚叶酸（HDFA）和5-氟尿嘧啶（5-FU）治疗晚期乳腺癌试验结果的更新情况。38例晚期且主要为难治性乳腺癌患者接受了以下治疗方案：HDFA（200mg/m²/天），随后立即给予5-FU（340、370、400mg/m²/天），每4周连续给药5天。在36例可评估患者中，3例实现完全缓解（8%），13例部分缓解（36%），总缓解率为44%，而11例患者（30%）病情稳定。16例缓解者中有13例（85%）曾接受过含5-FU的某些治疗方案预处理。缓解的中位持续时间为9.6+个月，缓解者、病情稳定或进展患者的中位生存期分别为19.9+、18.8+和9个月。总体毒性可接受：血液学毒性非常轻微，而口腔黏膜炎、腹泻和结膜炎是主要副作用。这些结果似乎很有前景，值得进一步评估。
